SI2284167T2 - Kristalinične oblike 4-metil-N-(3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil)-3-(4- piridin-3-il-pirimidin-2-ilamino)-benzamida - Google Patents

Kristalinične oblike 4-metil-N-(3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil)-3-(4- piridin-3-il-pirimidin-2-ilamino)-benzamida

Info

Publication number
SI2284167T2
SI2284167T2 SI200632162T SI200632162T SI2284167T2 SI 2284167 T2 SI2284167 T2 SI 2284167T2 SI 200632162 T SI200632162 T SI 200632162T SI 200632162 T SI200632162 T SI 200632162T SI 2284167 T2 SI2284167 T2 SI 2284167T2
Authority
SI
Slovenia
Prior art keywords
methyl
ylamino
benzamide
imidazol
pyrimidin
Prior art date
Application number
SI200632162T
Other languages
English (en)
Other versions
SI2284167T1 (sl
Inventor
Paul W. Manley
Wen-Chung Shieh
Paul Allen Sutton
Piotr H. Karpinski
Raeann Wu
Stephanie Monnier
Jorg Brozio
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37451227&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2284167(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SI2284167T1 publication Critical patent/SI2284167T1/sl
Publication of SI2284167T2 publication Critical patent/SI2284167T2/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SI200632162T 2005-07-20 2006-07-18 Kristalinične oblike 4-metil-N-(3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil)-3-(4- piridin-3-il-pirimidin-2-ilamino)-benzamida SI2284167T2 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70140505P 2005-07-20 2005-07-20
US71621405P 2005-09-12 2005-09-12
EP10173956.3A EP2284167B2 (en) 2005-07-20 2006-07-18 Crystalline form of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide

Publications (2)

Publication Number Publication Date
SI2284167T1 SI2284167T1 (sl) 2017-05-31
SI2284167T2 true SI2284167T2 (sl) 2020-03-31

Family

ID=37451227

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200632162T SI2284167T2 (sl) 2005-07-20 2006-07-18 Kristalinične oblike 4-metil-N-(3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil)-3-(4- piridin-3-il-pirimidin-2-ilamino)-benzamida
SI200631365T SI1912973T1 (sl) 2005-07-20 2006-07-18 Kristalinične oblike 4-metil-N-(3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil)-3- (4-piridin-3-il-pirimidin-2-ilamino)-benzamida

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200631365T SI1912973T1 (sl) 2005-07-20 2006-07-18 Kristalinične oblike 4-metil-N-(3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil)-3- (4-piridin-3-il-pirimidin-2-ilamino)-benzamida

Country Status (43)

Country Link
US (4) US8343984B2 (sl)
EP (5) EP2284167B2 (sl)
JP (3) JP5289948B2 (sl)
KR (3) KR20130085444A (sl)
CN (2) CN103804356A (sl)
AR (1) AR054846A1 (sl)
AU (3) AU2006276204A1 (sl)
BR (1) BRPI0613615B1 (sl)
CA (1) CA2614334C (sl)
CR (1) CR9657A (sl)
CU (1) CU23916B1 (sl)
CY (2) CY1113076T1 (sl)
DK (2) DK2284167T4 (sl)
EA (2) EA016856B1 (sl)
EC (1) ECSP088119A (sl)
ES (3) ES2648288T3 (sl)
GE (1) GEP20115302B (sl)
GT (1) GT200600315A (sl)
HK (1) HK1116783A1 (sl)
HN (1) HN2008000311A (sl)
HR (2) HRP20120573T1 (sl)
HU (1) HUE031791T2 (sl)
IL (2) IL188189A0 (sl)
JO (1) JO3308B1 (sl)
LT (1) LT2284167T (sl)
MA (1) MA29626B1 (sl)
MX (1) MX2008000899A (sl)
MY (1) MY148554A (sl)
NI (1) NI200800017A (sl)
NO (1) NO341930B1 (sl)
NZ (1) NZ564409A (sl)
PE (1) PE20070214A1 (sl)
PH (1) PH12013501590A1 (sl)
PL (2) PL2284167T5 (sl)
PT (2) PT1912973E (sl)
RS (1) RS55929B2 (sl)
SG (1) SG163620A1 (sl)
SI (2) SI2284167T2 (sl)
SM (1) SMAP200800011A (sl)
TN (1) TNSN08029A1 (sl)
TW (1) TWI406661B (sl)
UA (1) UA94234C2 (sl)
WO (1) WO2007015870A2 (sl)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200600316A (es) 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
GT200600315A (es) 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
AU2007235976A1 (en) * 2006-04-07 2007-10-18 Novartis Ag Use of c-Src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia
EP1923053A1 (en) 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
WO2009082662A1 (en) 2007-12-21 2009-07-02 Novartis Ag Combination of nilotinib and a nitrogen mustard analogue for the treatment of chronic lymphocytic leukemia
WO2010009402A2 (en) * 2008-07-17 2010-01-21 Teva Pharmaceutical Industries Ltd. Nilotinib intermediates and preparation thereof
WO2010054056A2 (en) 2008-11-05 2010-05-14 Teva Pharmaceutical Industries Ltd. Nilotinib hci crystalline forms
EP2186514B1 (en) 2008-11-14 2016-06-29 Kinki University Treatment of Malignant Peripheral Nerve Sheath Tumors
CA2753637A1 (en) 2009-03-06 2010-09-10 Novartis Ag Use of pyrimidylaminobenzamide derivatives for the treatment of disorders mediated by the leucine zipper- and sterile alpha motif-containing kinase (zak)
TW201102068A (en) 2009-06-02 2011-01-16 Novartis Ag Treatment of ophthalmologic disorders mediated by alpha-carbonic anhydrase isoforms
RU2012120901A (ru) 2009-10-23 2013-12-10 Новартис Аг Способ лечения пролиферативных расстройств и других патологических состояний, опосредованных действием киназ bcr-abl, c-kit, ddr1, ddr2 или pdgf-r
JO3634B1 (ar) 2009-11-17 2020-08-27 Novartis Ag طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r
WO2011086541A1 (en) * 2010-01-15 2011-07-21 Generics [Uk] Limited Novel polymorph of nilotinib monohydrochloride monohydrate
WO2011128434A2 (en) 2010-04-16 2011-10-20 Novartis Ag Treatment of endocrine resistant breast cancer
EP2382976A1 (en) 2010-04-30 2011-11-02 Hiroshima University Use of pdgf-r inhibitors for the treatment of lymph node metastasis of gastric cancer
KR20130042498A (ko) 2010-06-21 2013-04-26 테바 파마슈티컬 인더스트리즈 리미티드 닐로티닙 염 및 이의 결정형
CN102453024B (zh) * 2010-10-27 2014-09-03 浙江九洲药业股份有限公司 一种尼罗替尼盐酸盐晶型及其制备方法
US8703788B2 (en) * 2010-11-26 2014-04-22 Bandi Parthasaradhi Reddy Polymorph of nilotinib hydrochloride
AR086913A1 (es) * 2011-06-14 2014-01-29 Novartis Ag 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
WO2013063000A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
WO2013063003A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
SG10201707768RA (en) 2011-11-14 2017-10-30 Novartis Ag Immediate release 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-methyl- 1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide formulation
ES2564969T3 (es) * 2012-02-09 2016-03-30 Natco Pharma Limited Proceso para la preparación de clorhidrato de nilotinib
WO2013120852A1 (en) 2012-02-13 2013-08-22 Grindeks, A Joint Stock Company Intermediates for a novel process of preparing imatinib and related tyrosine kinase inhibitors
US9061028B2 (en) 2012-02-15 2015-06-23 Natco Pharma Limited Process for the preparation of Nilotinib
EP2872142A1 (en) 2012-07-11 2015-05-20 Novartis AG Method of treating gastrointestinal stromal tumors
US9376419B2 (en) 2012-10-15 2016-06-28 Apotex Inc. Solid forms of nilotinib hydrochloride
US9567317B2 (en) 2012-10-19 2017-02-14 Basf Se Multicomponent crystalline system comprising nilotinib and selected co-crystal formers
CN105008357A (zh) * 2013-02-21 2015-10-28 辉瑞大药厂 选择性cdk4/6抑制剂的固态形式
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
EP3461818A1 (en) * 2013-04-24 2019-04-03 Dr. Reddy's Laboratories Ltd. Polymorphic forms of nilotinib hydrochloride
RU2551359C9 (ru) * 2013-11-28 2021-08-20 Общество с ограниченной ответственностью "Мамонт Фарм" Наноразмерная слабо закристаллизованная модификация 4-метил-N-[3-(4-метилимидазол-1-ил)-5-(трифторметил)фенил]-3-[(4-пиридин-3-илпиримидин-2-ил)амино]бензамида гидрохлорида моногидрата, способ ее получения и фармацевтическая композиция на ее основе
WO2015092624A1 (en) 2013-12-16 2015-06-25 Ranbaxy Laboratories Limited Nilotinib mono-oxalate and its crystalline form
WO2016020891A1 (en) 2014-08-08 2016-02-11 Dr. Reddy’S Laboratories Limited Process for the preparation of polymorphic forms of nilotinib
WO2016058081A1 (en) * 2014-10-16 2016-04-21 Apotex Inc. Solid forms of nilotinib hydrochloride
EP3408264B1 (en) 2016-01-26 2020-03-11 Farma GRS, d.o.o. Nilotinib dinitrate (v) and crystalline forms thereof
WO2017149550A1 (en) * 2016-03-02 2017-09-08 Msn Laboratories Private Limited Amorphous form of 4-methyl-n-[3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzamide
DK3430004T3 (da) 2016-03-14 2020-09-28 Pliva Hrvatska D O O Faststofformer af nilotinibsalte
CN106496193A (zh) * 2016-09-13 2017-03-15 福格森（武汉）生物科技股份有限公司 一种高纯度尼罗替尼的制备方法
EP3404025B1 (en) 2017-05-16 2019-12-04 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Process for the preparation of pure nilotinib and its salt
CZ2017821A3 (cs) 2017-12-20 2019-07-03 Zentiva, K.S. Léková forma obsahující krystalický nilotinib
WO2019241504A1 (en) 2018-06-15 2019-12-19 Handa Pharmaceuticals, Llc Kinase inhibitor salts and compositions thereof
JP2020007240A (ja) * 2018-07-04 2020-01-16 住友化学株式会社 ベンズアミド化合物の製造方法
US20210380557A1 (en) * 2018-11-05 2021-12-09 Laurus Labs Limited Crystalline form of nilotinib hydrochloride, process for its preparation and pharmaceutical composition containing the same
IL295007A (en) 2020-01-31 2022-09-01 Nanocopoeia Llc Amorphous nilotinib microparticles and uses thereof
WO2021222739A1 (en) 2020-04-30 2021-11-04 Nanocopoeia, Llc Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
CN114133378B (zh) * 2020-09-04 2023-08-15 成都苑东生物制药股份有限公司 一种盐酸尼洛替尼共晶及其制备方法
WO2022263510A1 (en) 2021-06-19 2022-12-22 Helm Ag Granulate composition comprising nilotinib
EP4122452A1 (en) 2021-07-23 2023-01-25 KRKA, d.d., Novo mesto Pharmaceutical composition comprising nilotinib and method of manufacturing the same
EP4260848A1 (en) 2022-04-11 2023-10-18 Lotus Pharmaceutical Co., Ltd. Pharmaceutical composition for solid dosage form containing nilotinib and process for its preparation
CN116102540A (zh) * 2023-01-05 2023-05-12 浙江工业大学 两种尼洛替尼游离碱新晶型及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US701406A (en) 1901-07-16 1902-06-03 Thomas K Jones Cut-off-valve mechanism.
US701405A (en) 1902-02-17 1902-06-03 Archibald White Maconochie Ejecting device for stamping-machines.
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GB0325031D0 (en) 2003-10-27 2003-12-03 Novartis Ag Organic compounds
SI1686997T1 (sl) * 2003-11-18 2009-08-31 Novartis Ag Inhibitorji mutantne oblike KIT
GT200600315A (es) 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
GT200600316A (es) 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.

Also Published As

Publication number Publication date
AU2012201453B2 (en) 2013-09-05
JP5289948B2 (ja) 2013-09-11
JO3308B1 (ar) 2018-09-16
WO2007015870A3 (en) 2007-06-07
EA016856B1 (ru) 2012-08-30
AU2012201453A1 (en) 2012-04-05
NO341930B1 (no) 2018-02-19
TNSN08029A1 (en) 2009-07-14
JP2013018789A (ja) 2013-01-31
PE20070214A1 (es) 2007-04-02
MA29626B1 (fr) 2008-07-01
KR20080027853A (ko) 2008-03-28
HRP20170634T4 (hr) 2020-02-07
JP5798101B2 (ja) 2015-10-21
EP2284168A3 (en) 2011-04-13
US20130023548A1 (en) 2013-01-24
KR20130085444A (ko) 2013-07-29
UA94234C2 (uk) 2011-04-26
SMP200800011B (it) 2008-02-27
PT2284167T (pt) 2017-05-15
HK1116783A1 (sl) 2009-01-02
ES2648288T3 (es) 2017-12-29
EA013464B1 (ru) 2010-04-30
SI1912973T1 (sl) 2012-08-31
CA2614334C (en) 2015-04-21
US20140343087A1 (en) 2014-11-20
LT2284167T (lt) 2017-04-25
DK2284167T3 (en) 2017-05-01
DK1912973T3 (da) 2012-07-23
EP1912973B1 (en) 2012-06-13
US20080269269A1 (en) 2008-10-30
CR9657A (es) 2008-04-16
PH12013501590A1 (en) 2015-09-21
EP2543665A3 (en) 2013-05-29
AR054846A1 (es) 2007-07-18
SMAP200800011A (it) 2008-02-27
PL2284167T5 (pl) 2020-07-27
NO20080820L (no) 2008-04-15
PL2284167T3 (pl) 2017-07-31
US8343984B2 (en) 2013-01-01
US8415363B2 (en) 2013-04-09
SI2284167T1 (sl) 2017-05-31
BRPI0613615B1 (pt) 2022-02-08
EP1912973A2 (en) 2008-04-23
KR101651288B1 (ko) 2016-08-25
KR20130077915A (ko) 2013-07-09
GT200600315A (es) 2007-03-19
HRP20170634T1 (hr) 2017-06-30
EP2284167A3 (en) 2011-03-02
EP2284168A2 (en) 2011-02-16
HN2008000311A (es) 2011-01-24
CN102358736A (zh) 2012-02-22
US20130165465A1 (en) 2013-06-27
IL188189A0 (en) 2008-03-20
AU2006276204A1 (en) 2007-02-08
GEP20115302B (en) 2011-10-10
TWI406661B (zh) 2013-09-01
HRP20120573T1 (hr) 2012-08-31
ECSP088119A (es) 2008-02-20
US8829015B2 (en) 2014-09-09
JP2014221831A (ja) 2014-11-27
CU23916B1 (es) 2013-07-31
EA201000145A1 (ru) 2010-06-30
EP2284167A2 (en) 2011-02-16
NZ564409A (en) 2011-07-29
CU20080006A7 (es) 2011-02-24
CY1113076T1 (el) 2016-04-13
CA2614334A1 (en) 2007-02-08
RS55929B1 (sr) 2017-09-29
CY1119624T1 (el) 2018-04-04
IL214659A0 (en) 2011-09-27
WO2007015870A2 (en) 2007-02-08
DK2284167T4 (da) 2020-03-02
ES2386974T3 (es) 2012-09-10
PL1912973T3 (pl) 2012-09-28
EP2535337B1 (en) 2017-08-23
JP2009502795A (ja) 2009-01-29
ES2623608T5 (es) 2020-06-18
RS55929B2 (sr) 2020-12-31
SG163620A1 (en) 2010-08-30
EP2284167B2 (en) 2019-11-27
AU2011202047A1 (en) 2011-05-26
TW200740793A (en) 2007-11-01
EP2535337A1 (en) 2012-12-19
MX2008000899A (es) 2008-03-18
NI200800017A (es) 2009-03-03
BRPI0613615A2 (pt) 2011-01-18
MY148554A (en) 2013-04-30
AU2012201453C1 (en) 2024-05-23
CN103804356A (zh) 2014-05-21
PT1912973E (pt) 2012-09-03
ES2623608T3 (es) 2017-07-11
EP2284167B1 (en) 2017-02-01
EP2543665A2 (en) 2013-01-09
EA200800201A1 (ru) 2008-06-30
HUE031791T2 (en) 2017-08-28

Similar Documents

Publication Publication Date Title
SI2284167T1 (sl) Kristalinične oblike 4-metil-N-(3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil)-3-(4- piridin-3-il-pirimidin-2-ilamino)-benzamida
IL187787A0 (en) Salts of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
IL187845A0 (en) Polymorphs of ethyl 3-[(2-{[4-(hexyloxycarbonylamino-iminomethyl)
IL183380A0 (en) Crystalline forms of linezolid intermediate
IL181297A0 (en) Benzamide compounds
PL1896425T3 (pl) Sposób wytwarzania 5-(metylo-1H-1-ilo)-3-trifluorometylo)-benzenoaminy
TWI341532B (en) Memory channel response scheduling
ZA200710799B (en) Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethylphenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
EP1858844A4 (en) NEW CRYSTALLINE FORMS OF ANTIDIABETIC COMPOUNDS
ZA200710457B (en) Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoro-methyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
GB0427758D0 (en) Novel benzamide compounds
SI1814858T1 (sl) Nove kristalne oblike nelfinavir mesilata
ZA200701801B (en) Benzamide compounds
PL377984A1 (pl) Sposób wytwarzania N-(5-amino-2-metylofenylo)-4-(3-pirydylo)-2-pirymidynoaminy
GB0522351D0 (en) Improvements related to the manufacture of pocketed coil springs
GB0422648D0 (en) Benzamide compounds